SEZ6L2

Across TCGA pan-cancer cohorts, SEZ6L2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SEZ6L2 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SEZ6L2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SEZ6L2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where SEZ6L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.580	0.916	.011	17	view →
HNSC	DFS	Tertile	III,IV	0.686	0.973	.001	14	view →
LSCC	OS	Median	III,IV	0.448	0.882	.008	14	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	10	view →
GBM	DFS	Quartile	All	0.803	0.630	.008	7	view →
UCEC	DFS	Median	II,III,IV	0.547	0.869	.041	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SEZ6L2–CCRCC (DFS)

Open the CCRCC breakdown →